MAPK and PI3K/Akt pathways are interlinked in TGF-β and ErbB2 signaling transduction and have been reported to promote trastuzumab resistance in breast cancer models and primary malignancies (31, –33). This evidence concerns the gene ERBB2 and breast carcinoma.